Real-time imaging shows that bacterial resilience to antibiotics is not caused by a few ‘persisters’, but is a ...

An Albuquerque-based firm is taking its first steps into a potentially game-changing partnership through an SBIR Phase I ...

This important study presents compelling observational data supporting a role for transcription and polysome accumulation in the separation of newly replicated bacterial chromosomes. The study is ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

The results are in. The "Best in Show" represents a product that stands out for performance, safety and user experience. You ...

IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with ...

New Jersey-based biotechnology company, Grignard Pure LLC, a leader in developing next-generation indoor air treatment ...

Africa is grappling with severe food insecurity in the wake of consecutive droughts, climate change, and ongoing conflicts, which are affecting millions across the continent.

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...

The analysis of the "feces" shows that both fermented and unfermented seaweed stimulates the growth of beneficial gut bacteria ... "It's been a long launch phase, but we are beginning to ...